Clinical outcomes of generic versus brand‐name clopidogrel for secondary prevention in patients with acute myocardial infarction: A nationwide cohort study
Abstract Skepticism exists among healthcare workers and patients regarding the efficacy and safety of generic medication, despite its potential to lower healthcare costs. This study aimed to compare the outcomes of a generic clopidogrel and its brand‐name counterpart for secondary prevention in pati...
Main Authors: | Cze Ci Chan, Ying‐Chang Tung, Kuang‐Tso Lee, Yi‐Hsin Chan, Pao‐Hsien Chu |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-09-01
|
Series: | Clinical and Translational Science |
Online Access: | https://doi.org/10.1111/cts.13590 |
Similar Items
-
Levosimendan use in patients with acute heart failure and reduced ejection fraction with or without severe renal dysfunction in critical cardiac care units: a multi-institution database study
by: Cze-Ci Chan, et al.
Published: (2021-02-01) -
Outcomes after ticagrelor versus clopidogrel treatment in end-stage renal disease patients with acute myocardial infarction: a nationwide cohort study
by: Ying-Chang Tung, et al.
Published: (2021-10-01) -
Platelet reactivity on brand and generic clopidogrel chronic therapy
by: Shukri AlSaif, et al.
Published: (2018-10-01) -
Clopidogrel and metoprolol in myocardial infarction - Reply
by: Chen, Z, et al.
Published: (2006) -
Case report: Sudden cardiorespiratory collapse in a healthy male after coronavirus disease 2019 vaccination at a vaccination center
by: Cze Ci Chan, et al.
Published: (2022-09-01)